Why the New Lupus Drug isn't for Everyone

April 26, 2011 - PRLog -- There is an immense amount of excitement and hope brewing among the SLE population with the recent FDA approval of the lupus treatment, Benlysta® (belimumab). This is the first medication the FDA has approved for SLE in over fifty years.

However, what hasn't been widely explained, is it isn't for everyone battling with Lupus.

In this month's edition of The Lupus Magazine, Kim Nault had the opportunity to ask Holly V. Russell, US Media Relations at Glaxo Smith Kline some questions about Benlysta® (belimumab).

"While the FDA approval of this novel DMARD is indeed a cause for celebration, it still has yet to gain the confidence of both patients and practitioners in effectively treating those with vital organ involvement.   Despite the fact that the Benlysta phase III studies did show objective measures of remittance in immunology, musculoskeletal and mucocutaneous manifestations, the studies did exclude people with active nephritis or central nervous system involvement," writes Nault.

To find out more about this drug and to read Kim's insightful interview, see this month's edition of The Lupus Magazine...  independent and online free every month.

http://www.thelupusmagazine.com/

The Lupus Magazine: For those with lupus, by those with lupus - www.thelupusmagazine.com

# # #

Published monthly, The Lupus Magazine has been established as we search worldwide for a cure for lupus. It's a place where you can enjoy the latest lupus news and articles from around the world.